Enforcement Updates in Brief
This article was originally published in The Gold Sheet
Executive Summary
FDA import alerts hit Chinese firms and Teva; EU GMP suspensions hit Bend Research and several Indian firms.
You may also be interested in...
FDA Warning Letter Slams Another Asian API Firm On Data Integrity
Data integrity warning letter to Chinese API maker reflects continuing focus of FDA enforcement efforts on the pharmaceutical industry's Asian supply chain.
Roivant Cuts Multiple R&D Programs As It Takes On Pfizer’s TYK2/JAK1 Inhibitor
Roivant and Pfizer launched Priovant to develop the oral drug brepocitinib for dermatomyositis, lupus and other autoimmune diseases, but Roivant also cut programs to extend its cash runway.
US FDA May Play Central Role In Assuring Access To Mifepristone Post Roe v. Wade
HHS will take steps to increase access to abortion medication and prevent states from banning it, Secretary Becerra says, but also is questioned about whether the FDA can speed up certification of pharmacies and if the Justice Department would sue states banning access.